Capivasertib is an AKT inhibitor designed for HR /HER2breast cancer patients with PIK3CA, AKT1, and PTEN alterations. It really targets that AKT signaling. There are two strengths to choose from: 200 mg and 400 mg tablets.
For adults, the dose is usually 400 mg, taken twice a day. You take it for 4 days straight and then take a break for 3 days. Each pack has 64 tablets in it.
Reviews
There are no reviews yet.